Skip to main content
. Author manuscript; available in PMC: 2010 May 1.
Published in final edited form as: J Clin Psychiatry. 2008 May;69(5):732–740. doi: 10.4088/jcp.v69n0506

Table 2.

Characteristics of Study Treatment Received

Low Family Impairment
High Family Impairment
Characteristic Total Sample (N = 91) Pharmacotherapy (N=15) Family Therapy (N = 7) Psychoeducational Group (N = 9) Pharmacotherapy (N=14) Family Therapy(N = 25) Psychoeducational Group (N = 21)
Early dropout, < 2 months, N% 9 (10) 2 (13) 2 (29) 0 (0) 1 (7) 1 (4) 3 (14)
Completed ≥ 6 months of randomized treatment, N (%) 59 (65) 12 (80) 4 (57) 7 (78) 7 (50) 16 (64) 13 (62)
Month of randomized treatment discontinuation, mean (SD) 14.8 (11 .5) 17.3 (11.2) 13.6 (13.7) 13.6 (9.7) 11.3 (11.6) 15.4 (11.6) 14.6 (12.0)
Completed 28 months of randomized treatment, N (%) 33 (36) 7 (47) 3 (43) 2 (22) 3 (21) 10 (40) 8 (38)
Mood stabilizer, adequate dose, N (%) 82 (90) 13 (87) 6 (86) 9 (100) 11 (79) 23 (92) 20 (95)
Antidepressant use, N (%) 46 (51) 5 (33) 3 (43) 6 (67) 6 (43) 16 (64) 10 (48)
Neuroleptic use, N(%) 72 (79) 14 (93) 5 (71) 8 (89) 12 (86) 18 (72) 15 (71)
No. of pharmacotherapy visits, mean (SD) 12.8 (8.9) 13.5 (7.7) 16.7 (15.6) 13.0 (7.4) 9.9 (8.4) 13.7 (8.9) 11.3 (8.5)
No. of family therapy visits, mean (SD) 11.9 (12.9) NA 12.8 (12.1) NA NA 11.6 (12.1) NA
No. of psychoeducational group meetings, mean (SD) 3.9 (2.5) NA NA 4.6 (2.2) NA NA 3.7 (2.6)

Abbreviation: NA = not applicable.